Molecular characterization of 8-methoxyfluoroquinolone resistance in a clinical isolate of methicillin-resistant Staphylococcus aureus

Chemotherapy

Volumn 53, Issue 2, 2007, Pages 104-109

  Horii, Toshinobu ^a   Suzuki, Yasuhiro ^b   Takeshita, Akihiro ^a   Maekawa, Masato ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

8 Methoxyfluoroquinolone; Antibiotic resistance; Fluoroquinolone; Methicillin resistant Staphylococcus aureus; Septicemia

Indexed keywords

8 METHOXYFLUOROQUINOLONE; AMINO ACID; ANTIINFECTIVE AGENT; BIAPENEM; CEFALORIDINE; CEFDINIR; CEFPIROME; CIPROFLOXACIN; CLOXACILLIN; DALFOPRISTIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; FLEROXACIN; GATIFLOXACIN; GLUTAMIC ACID; GLUTAMINE; HABEKACIN; LEVOFLOXACIN; NORFLOXACIN; OFLOXACIN; PAZUFLOXACIN; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; QUINUPRISTIN; SERINE; SITAFLOXACIN; TEICOPLANIN; TELITHROMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD CULTURE; CASE REPORT; DNA SEQUENCE; GENE MUTATION; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SEPTICEMIA;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BASE SEQUENCE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33847744227     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098427     Document Type: Article

References (36)

1. Hooper DC: Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001;7:337-341.
2. Horii T, Suzuki Y, Monji A, Morita M, Muramatsu H, Kondo Y, Doi M, Takeshita A, Kanno T, Maekawa M: Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 2003;46:139-145.
3. Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Köhrer K, Milatovic D: Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol 1999;26:281-287.
4. Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K: In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992;36:2108-2117.
5. Wakabayashi E, Mitsuhashi S: In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1994;38:594-601.
6. Jones RN, Beach ML, Pfaller MA, Doern GV: Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant Gram-positive cocci isolated from patient infections in North and South America. Diagn Microbiol Infect Dis 1998;32:247-252.
7. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D: In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000;45:437-446.
8. Yoshida H, Bogaki M, Nakamura S, Ubukata K, Konno M: Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990;172:6942-6949.
9. Kaatz GW, Seo SM, Ruble CA: Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993;37:1086-1094.
10. Takenouchi T, Ishii C, Sugawara M, Tokue Y, Ohya S: Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother 1995;39:1414-1418.
11. Wang T, Tanaka M, Sato K: Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob Agents Chemother 1998;42:236-240.
12. Fukuda H, Hori S, Hiramatsu K: Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother 1998;42:1917-1922.
13. Piddock LJV: Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1998;58(suppl 2):11-18.
14. Schmitz FJ, Hertel B, Hofmann B, Scheuring S, Verhoef J, Fluit AC, Heinz HP, Köhrer K, Jones ME: Relationship between mutations in the coding and promoter regions of the norA genes in 42 unrelated clinical isolates of Staphylococcus aureus and the MICs of norfloxacin for these strains. J Antimicrob Chemother 1998;42:561-563.
15. Linde HJ, Schmidt M, Fuchs E, Reischl U, Niller HH, Lehn N: In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob Agents Chemother 2001;45:1553-1557.
16. Ince D, Hooper DC: Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:2755-2764.
17. Kim MJ, Yun HJ, Kang JW, Kim S, Kwak JH, Choi EC: In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates. J Antimicrob Chemother 2003;51:1011-1016.
18. Bogdanovich T, Esel D, Kelly LM, Bozdogan B, Credito K, Lin G, Smith K, Ednie LM, Hoellman DB, Appelbaum PC: Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob Agents Chemother 2005;49:3325-3333.
19. Fluit AC, Visser MR, Schmitz FJ: Molecular detection of antimicrobial resistance. Clin Microbiol Rev 2001;14:836-871.
20. Takei M, Fukuda H, Kishii R, Hosaka M: Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activity and target inhibition. Antimicrob Agents Chemother 2001;45:3544-3547.
21. Lemmen SW, Häfner H, Klik S, Lütticken R, Zolldann D: Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. Chemotherapy 2003;49:33-35.
22. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, ed 5. Approved Standard M7-A6. Wayne, NCCLS, 2004.
23. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, ed 2. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1989.
24. Muramatsu H, Horii T, Takeshita A, Hashimoto H, Maekawa M: Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa. Chemotherapy 2005;51:70-75.
25. Hirai K, Aoyama H, Irikura T, Iyobe S, Mitsuhashi S: Difference in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother 1996;29:535-538.
26. Boos M, Mayer S, Fischer A, Kohrer K, Scheuring S, Heisig P, Verhoef J, Fluit AC, Schmitz FJ: In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:938-942.
27. Roychoudhury S, Twinem TL, Makin KM, Nienaber MA, Li C, Morris TW, Ledoussal B, Catrenich CE: Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations. Antimicrob Agents Chemother 2001;45:3422-3426.
28. Sreedharan S, Oram M, Jensen B, Peterson LR, Fisher LM: DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. J Bacteriol 1990;172:7260-7262.
29. Goswitz JJ, Willard KE, Fasching CE, Peterson LR: Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob Agents Chemother 1992;36:1166-1169.
30. Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F: Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 1994;13:641-653.
31. Tanaka M, Zhang YX, Ishida H, Akasaka T, Sato K, Hayakawa I: Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China. J Med Microbiol 1995;42:214-219.
32. Yamagishi J, Kojima T, Oyamada Y, Fujimoto K, Hattori H, Nakamura S, Inoue M: Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996;40:1157-1163.
33. Tanaka M, Onodera Y, Uchida Y, Sato K, Hayakawa I: Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:2362-2366.
34. Cambau E, Perani E, Dib C, Petinon C, Trias J, Jarlier V: Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother 1995;39:2248-2252.
35. Griggs DJ, Marona H, Piddock LJV: Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones. J Antimicrob Chemother 2002;51:1403-1407.
36. Trucksis M, Hooper DC, Wolfson JS: Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med 1991;114:424-426.